Iovance Biotherapeutics
IOVA
82 hedge funds and large institutions have $357M invested in Iovance Biotherapeutics in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 9 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
93% more capital invested
Capital invested by funds: $185M → $357M (+$172M)
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
6% more funds holding
Funds holding: 77 → 82 (+5)
91% less call options, than puts
Call options by funds: $841K | Put options by funds: $9.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$14.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$7.62M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$7.6M |
| 4 |
BC
Broadfin Capital
New York
|
+$6.69M |
| 5 |
PA
Perceptive Advisors
New York
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.42M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$3.01M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.23M |
| 4 |
NC
Nexthera Capital
New York
|
-$774K |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$572K |
IOVA Hedge Fund Activity: Q2 2016 in Review
82 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2016, worth a combined $357M — up 93% from $185M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IOVA positions and 9 closed out — a net gain of 5 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was OrbiMed, adding an estimated $14.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $5.42M sold.
- 82 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2016, up from 77 in Q1 2016.
- Funds reported $357M of Iovance Biotherapeutics stock for Q2 2016, up 93% quarter-over-quarter.
- 14 funds opened new Iovance Biotherapeutics positions in Q2 2016 and 9 closed out, a net change of +5 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2016 was OrbiMed, an estimated $14.8M added.
- The largest Iovance Biotherapeutics seller in Q2 2016 was Baker Bros. Advisors, an estimated $5.42M sold.
Based on aggregated 13F filings for Q2 2016.